OcuTerra Therapeutics completed enrollment in the phase 2 DR:EAM clinical trial, which is investigating OTT166 eye drops for the treatment of diabetic retinopathy, according to a press release.
The multicenter, randomized, double-masked trial is assessing the safety and efficacy of OTT166, a small molecule RGD integrin inhibitor. Two hundred twenty-five adult patients with moderately severe to severe nonproliferative diabetic retinopathy or mild proliferative diabetic retinopathy were randomly assigned to receive either one of two doses of OTT166 or vehicle.
The primary efficacy study endpoints